Stand Up To Cancer With Support From Bristol Myers Squibb Unveils New Lung Cancer PSA Featuring Artist, Actor and Activist Common - Stand Up To Cancer

Press

Posted November 3, 2021

SU2C and BMS logo

Stand Up To Cancer With Support From Bristol Myers Squibb Unveils New Lung Cancer PSA Featuring Artist, Actor and Activist Common

Photo

LOS ANGELES November 4, 2021 – Stand Up To Cancer® (SU2C) announced today the launch of a new public service announcement (PSA) campaign, in collaboration with Academy, Emmy® and Grammy® Award-winning artist, actor, activist and SU2C Ambassador Common, and with support from Bristol Myers Squibb. The PSA raises awareness for lung cancer research and clinical trials. Lung cancer is the leading cause of cancer death among both men and women in the United States and represents nearly 25% of all cancer deaths.

In the new broadcast PSA, Common highlights the profound impact lung cancer continues to have on the Black community. The hopeful, empowering and educational campaign addresses the importance of screening and treatment options, including cancer clinical trials. The campaign will come to life across print, digital, radio and out-of-home media, with the print and radio PSA being released in both English and Spanish-language.

“In 2014 my father died after his battle with cancer,” said Common. “He was truly someone who inspired me and made me want to be better. I believe that we can do better for ourselves – especially as Black men when it comes to health. I’m honored to support Stand Up To Cancer’s campaign to bring awareness to lung cancer research.”

This new campaign is the latest effort from Stand Up To Cancer that is being supported by Bristol Myers Squibb, who has provided funding for important SU2C research initiatives since 2014. Both organizations are committed to promoting and improving health equity in medically underserved communities. This awareness campaign was supported by a $5 million grant awarded to SU2C from Bristol Myers Squibb last year to help fund research and education efforts aimed at achieving health equity for underserved lung cancer patients, including Black people and people living in rural communities. In 2020, Bristol Myers Squibb awarded Stand Up To Cancer a total of $10 million in grant funding to support lung cancer research.

“More than 235,000 new cases of lung cancer will be diagnosed this year in the United States and research shows there are stark disparities in lung cancer diagnoses among diverse and rural communities,” said Sung Poblete PhD, RN, CEO of Stand Up To Cancer. “Stand Up To Cancer is committed to saving lives by accelerating cancer research and reducing barriers to clinical trial participation in medically underserved communities. We are thankful to Bristol Myers Squibb for their collaboration to support our efforts in lung cancer research and to Common for lending his voice and support to this important campaign.”

Despite recent progress in treating lung cancer, the disease remains the leading cause of cancer death in the U.S. with particularly high death rates in rural communities and among Black men. Each year, over 25,000 Black men and women in the U.S. will be diagnosed with lung cancer. Black men are about 15% more likely to develop lung cancer than white men.

“Our mission at Bristol Myers Squibb is to transform lives through science, but that also means ensuring that all people affected by cancer can equally benefit from the latest science and treatments,” said Wendy Short Bartie, senior vice president, US Oncology, Bristol Myers Squibb. “By bringing visibility to lung cancer inequities and encouraging diversity in clinical trials, this PSA will take an important step toward eliminating the dangerous disparities that exist for many underserved lung cancer patients. That’s why it was a clear fit for us to continue our longtime support of Stand Up To Cancer by aligning on this effort.”

The broadcast and radio PSAs were developed by SU2C and production studio Society. The print campaign was produced by SU2C with photography by Matt Sayles.

This campaign is the latest in a series of PSAs by SU2C to increase awareness about the importance of cancer screenings and clinical trials in medically underserved communities. SU2C formally announced its Health Equity Initiative in January 2020. To date, the initiative has focused on increasing diversity in cancer clinical trials, initiating advocacy group collaborations and awareness campaigns, and funding research aimed at improving cancer outcomes and screening rates in medically underserved communities.

To learn more about this PSA visit, StandUpToCancer.org/LungCancer.

About Stand Up To Cancer
Stand Up To Cancer® (SU2C) raises funds to accelerate the pace of research to get new therapies to patients quickly and save lives now. SU2C, a division of the Entertainment Industry Foundation, a 501(c)(3) charitable organization, was established in 2008 by media and entertainment leaders who utilize these communities’ resources to engage the public in supporting a new, collaborative model of cancer research, to increase awareness about cancer prevention, and to highlight progress being made in the fight against the disease. As of September 2021, more than 2,000 scientists representing more than 210 institutions are involved in SU2C-funded research projects.

Under the direction of our Scientific Advisory Committee, led by Nobel laureate Phillip A. Sharp, Ph.D., SU2C conducts rigorous competitive review processes to identify the best research proposals to recommend for funding, oversee grants administration, and ensure collaboration across research programs.

Current members of the SU2C Founders and Advisors Committee (FAC) include Katie Couric, Sherry Lansing, Kathleen Lobb, Lisa Paulsen, Rusty Robertson, Sue Schwartz, Pamela Oas Williams, and Ellen Ziffren. The late Laura Ziskin and the late Noreen Fraser are also co-founders. Sung Poblete, Ph.D., R.N., serves as SU2C’s CEO, and Russell Chew as SU2C’s President.

For more information, visit StandUpToCancer.org, Instagram, TikTok, Twitter, Facebook, and YouTube.

About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedInTwitterYouTubeFacebook, and Instagram.

Media Contacts:            

Jade Waddy
Stand Up To Cancer
jwaddy@su2c.org

IDPR
SU2C@id-pr.com
646-723-3800

#  #  #

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Please validate the captcha
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.